Healthcare / BiotechnologyTaipei Exchange
$7.21
-0.11 (-1.52%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-144.8M · quality 77.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
15/100
F
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.1B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-60.9%
↓Gross Margin
N/A
•Debt/Equity
0.06
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
1.05x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-111.3M · FCF $-116.4M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | — | — | $118.8M | $236.9M | $270.2M |
| Net Income | $-111.3M | $-111.3M | $-183.5M | $-289.4M | $-152.9M |
| EBITDA | $-98.6M | $-98.6M | $-170.8M | $-266.4M | $-128.4M |
| EPS | — | — | -1.29 | -2.12 | -1.27 |
| Gross Margin | — | — | 27.7% | 42.0% | 45.6% |
| Operating Margin | — | — | -159.8% | -121.7% | -55.5% |
| Net Margin | — | — | -154.5% | -122.2% | -56.6% |
| Balance Sheet | |||||
| Debt/Equity | 0.06 | 0.06 | 0.05 | 0.92 | 0.06 |
| Current Ratio | 5.29 | 5.29 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-116.4M | $-116.4M | $-144.8M | $-280.8M | $-148.1M |
| Returns | |||||
| ROE | -60.9% | -60.9% | -62.4% | -347.1% | -29.3% |
| Valuation | |||||
| P/B | 5.76 | 5.76 | 6.12 | 31.25 | 7.19 |
| Growth & Yield | |||||
| Revenue Growth | — | — | -49.9% | -12.3% | — |
| EPS Growth | — | — | 39.2% | -66.6% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+1.7%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.29 → n/d
Residual
+1.7%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.